Nuveen
CRBP icon

Nuveen’s Corbus Pharmaceuticals CRBP Stock Holding History

Nuveen’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209K Buy
+22,308
New +$211K ﹤0.01% 3628
2025
Q2 		– Sell
-45,689
Closed -$243K – 3296
2025
Q1 		$243K Buy
45,689
+16,751
+58% +$148K ﹤0.01% 3079
2024
Q4 		$341K Sell
28,938
-101,232
-78% -$1.7M ﹤0.01% 3099
2024
Q3 		$2.69M Buy
130,170
+102,272
+367% +$5.23M ﹤0.01% 2280
2024
Q2 		$1.26M Buy
+27,898
New +$1.17M ﹤0.01% 2614
2021
Q2 		– Sell
-8,437
Closed -$2.34M – 3400
2021
Q1 		$2.34M Buy
8,437
+270
+3% +$17.7K ﹤0.01% 2543
2020
Q4 		$2.27M Hold
8,167
– – ﹤0.01% 2444
2020
Q3 		$2.27M Sell
8,167
-17,371
-68% -$3.15M ﹤0.01% 2315
2020
Q2 		$6.43M Buy
25,538
+17,122
+203% +$3.46M ﹤0.01% 1757
2020
Q1 		$1.32M Buy
8,416
+1,612
+24% +$273K ﹤0.01% 2389
2019
Q4 		$1.11M Hold
6,804
– – ﹤0.01% 2648
2019
Q3 		$994K Sell
6,804
-390
-5% -$67.9K ﹤0.01% 2707
2019
Q2 		$1.5M Buy
+7,194
New +$1.54M ﹤0.01% 2568

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Nuveen's CRBP Position: Q2 2026 in Review

Nuveen opened a new position in Corbus Pharmaceuticals (CRBP) in Q2 2026: 22,308 shares worth $209K. The stake represents ﹤0.01% of the portfolio and ranks #3628 among its holdings. This is a return to the name: Nuveen previously reported a position in CRBP as recently as Q1 2025.

Nuveen first reported a position in CRBP in Q2 2019 and has held it in 13 quarters since. The position peaked at $6.43M in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Nuveen held 22,308 shares of Corbus Pharmaceuticals worth $209K as of Q2 2026.
  • Corbus Pharmaceuticals was a new Nuveen position in Q2 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3628 holding.
  • Nuveen first reported a position in Corbus Pharmaceuticals in Q2 2019 and has held it in 13 quarters since.
  • Nuveen's Corbus Pharmaceuticals position peaked at $6.43M in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.